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ABSTRACT 
Purpose: Vitamin K antagonists (VKAs) are the standard of care for stroke prevention in patients 
with atrial fibrillation (AF); therefore, there is not equipoise when comparing newer oral 
anticoagulants with placebo in this setting.  
Methods: To explore the effect of apixaban on mortality in patients with AF, we performed a meta-
analysis of apixaban versus placebo using a putative placebo analysis based on randomized controlled 
clinical trials that compared warfarin, aspirin, and no antithrombotic control. We used data from 2 
prospective randomized controlled trials for our comparison of apixaban versus warfarin 
(ARISTOTLE) and apixaban versus aspirin (AVERROES). Using meta-analysis approaches, we 
indirectly compared apixaban with an imputed placebo with respect to the risk of death in patients 
with AF. We used results from meta-analyses of randomized trials as our reference for the comparison 
between warfarin and placebo/no treatment, and aspirin and placebo/no treatment.  
Results: In these meta-analyses, a lower rate of death was seen both with warfarin (odds ratio [OR] 
0.74, 95% confidence interval [CI] 0.57–0.97) and aspirin (OR 0.86, 95% CI 0.69–1.07) versus 
placebo/no treatment. Using data from ARISTOTLE and AVERROES, apixaban reduced the risk of 
death by 34% (95% CI 12–50%; p=0.004) and 33% (95% CI 6–52%; p=0.02), respectively, when 
compared with an imputed placebo. The pooled reduction in all-cause death with apixaban compared 
with an imputed placebo was 34% (95% CI 18–47%; p=0.0002). 
Conclusions: In patients with AF, indirect comparisons suggest that apixaban reduces all-cause death 
by approximately one-third compared with an imputed placebo. 
 
Keywords: apixaban, aspirin, placebo, mortality, warfarin, atrial fibrillation 
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INTRODUCTION 
Anticoagulation with vitamin K antagonists (VKAs) is highly effective for stroke prevention in 
patients with atrial fibrillation (AF) and, until recently, was the standard of care [1]. Thus, there is not 
equipoise when comparing newer oral anticoagulants with placebo in this setting.  
 Patients with AF are at high risk of death, an outcome more common than stroke [2,3], and 
strategies to improve survival in this population are needed. When compared with placebo (or 
control), warfarin is highly effective in reducing stroke in patients with AF; however, the effect of 
warfarin on mortality is less certain with a reported relative risk reduction of 26% (95% confidence 
interval [CI] 3–43%) of borderline significance in a meta-analysis of 6 trials including a total of 2900 
patients who experienced 110 versus 143 deaths. In similar meta-analyses, antiplatelet therapy, 
compared with placebo (or control), had a much more modest stroke benefit that was statistically 
uncertain with no significant effect on mortality. When compared directly with antiplatelet therapy, 
warfarin did not lead to a clear reduction in death. Subsequently, non-vitamin K antagonist oral 
anticoagulants (NOACs) were studied in large randomized trials and were at least as effective as 
warfarin at preventing stroke in patients with AF and generally safer than warfarin, particularly in 
causing less intracranial hemorrhage (ICH), when compared with warfarin [4-7]. Compared with 
warfarin, the NOACs also appeared to lead to modest reductions in mortality but with borderline 
statistical significance when individual trial results were analyzed [4-7]. However, a meta-analysis 
with pooled data from the 4 clinical trials that tested NOACs versus warfarin for patients with AF 
showed a highly significant reduction in all-cause mortality with NOACs compared with warfarin 
(relative risk [RR] 0.90, 95% CI 0.85–0.95; p=0.0003) [8]. One NOAC, apixaban, was also superior 
to aspirin in reducing the risk of stroke with a lower risk of death, which was statistically 
insignificant. Collectively, however, these observations suggest that the effects of NOACs on 
mortality, compared with placebo, could be substantial but are presently uncertain. Demonstrating a 
clear mortality benefit of anticoagulation would reinforce the value of this therapeutic strategy in AF. 
We have addressed this question in relation to apixaban as there are large randomized trials 
comparing this NOAC with both warfarin and aspirin, permitting indirect comparisons with a putative 
placebo derived from the aforementioned meta-analyses. Apixaban, a direct, selective factor Xa 
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inhibitor, was studied in 2 prospective randomized controlled trials in patients with AF at risk of 
stroke: Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation 
(ARISTOTLE) [4] and Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation 
Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) [9]. 
In ARISTOTLE, apixaban was compared with warfarin; AVERROES compared apixaban with 
aspirin. In both trials all-cause death was either a part of the hierarchical sequence of the primary 
analysis (ARISTOTLE) or a key secondary outcome (AVERROES). In each trial, rates of death were 
numerically lower with apixaban compared with the active control (warfarin or aspirin).  
 
METHODS 
We used the meta-analysis performed by Hart et al. [1] as a reference for the comparison between 
adjusted-dose warfarin and placebo/no treatment and between aspirin and placebo/no treatment. The 
ARISTOTLE trial was used for the comparison between apixaban and warfarin, and the AVERROES 
trial for the comparison between apixaban and aspirin. The outcome of interest for this analysis was 
all-cause death.  
 The protocols for both ARISTOTLE and AVERROES were approved by the ethics 
committee at each participating site, and all patients provided written informed consent before 
enrollment. 
 
Adjusted-dose warfarin compared with placebo/no treatment 
Hart et al. [1] pooled randomized trials that included patients with AF and investigated the efficacy of 
antithrombotic agents for stroke prevention in this population. Overall, 6 clinical trials that compared 
adjusted-dose warfarin with placebo/no treatment were identified, with a total of 2900 patients. The 
mean follow-up was 1.6 years.  
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Antiplatelet therapy compared with placebo/no treatment 
In the same meta-analysis, 8 randomized trials compared antiplatelet therapies (aspirin and/or 
dipyridamole) with placebo/no treatment, and included a total of 4876 patients. The mean 
follow-up was 1.7 years. Of those, 7 trials (n=3990) compared aspirin alone with placebo/no 
treatment and accounted for 76% of follow-up exposure. For our mortality analysis, we used 
data from 5 trials that compared aspirin with placebo/no treatment and had mortality 
information available (n=3730). Among those studies, the aspirin dose varied from 75 mg 
daily to 325 mg daily.  
 
The ARISTOTLE trial 
The ARISTOTLE trial included 18,201 patients with AF and at least 1 additional risk factor for 
stroke—age ≥75 years, previous stroke/transient ischemic attack (TIA), symptomatic heart failure, 
diabetes, or hypertension. Participants were randomly assigned to apixaban 5 mg twice daily or dose-
adjusted warfarin with a target international normalized ratio (INR) of 2.0 to 3.0. Apixaban 2.5 mg 
twice daily was given to participants with 2 or more of the following characteristics: age ≥80 years, 
body weight ≤60 kg, and serum creatinine ≥1.5 mg/dL. Key exclusion criteria included clinically 
significant mitral stenosis, prosthetic mechanical heart valve, previous intracranial bleeding, severe 
renal insufficiency, history of stroke within 7 days before randomization, and need for dual 
antiplatelet therapy. The median follow-up was 1.8 years. 
 
The AVERROES trial 
The AVERROES trial included 5599 patients with AF who were ≥50 years of age and had at least 1 
additional risk factor for stroke—age ≥75 years, previous stroke/TIA, symptomatic heart failure, 
diabetes, hypertension, or peripheral artery disease. To be included, patients should have been 
considered unsuitable for treatment with a vitamin K antagonist. Participants were randomized to 
receive apixaban 5 mg twice daily or aspirin at a dose of 81 to 324 mg per day. Criteria for receiving a 
lower dose of apixaban were the same as for the ARISTOTLE trial. Key exclusion criteria included 
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valvular disease requiring surgery, high risk of bleeding, severe renal insufficiency, and need for dual 
antiplatelet therapy. The mean follow-up was 1.1 years. The AVERROES trial was stopped early by 
the data and safety monitoring board because of a clear benefit in favor of apixaban versus aspirin in 
the reduction of stroke or systemic embolism; therefore, this trial accrued only approximately half of 
the initially expected events. 
 
Statistical analysis  
Figure 1 shows the comparisons made in the schematic format. The indirect comparison method 
proposed by Bucher et al. [10] was used to estimate the odds ratio (OR) of apixaban compared with 
placebo. Using historical active control data for warfarin versus placebo reported by Hart et al., the 
OR of apixaban versus placebo was estimated as the ratio of the OR for apixaban versus warfarin and 
warfarin versus placebo. The CI for the OR was derived in the logit scale and based on the statistical 
independence of the estimates combined. A similar approach was used to derive the apixaban versus 
placebo OR, using the aspirin versus placebo information. The method used was similar to that used 
by Fisher et al. (using OR) [11] and McMurray et al. (using hazard ratio) [12]. The 2 ORs for 
apixaban versus placebo were then combined using a random effects model using the DerSimonian 
and Laird method, and the heterogeneity between trials was also tested.  
This analysis assumes that the active control data (warfarin and aspirin) versus placebo 
estimate the same OR that would have occurred if the ARISTOTLE and AVERROES trials had 
included a placebo arm. 
 
RESULTS 
A summary of the study and patient characteristics in the Hart et al. meta-analysis, ARISTOTLE, and 
AVERROES is shown in Table 1. The mean age of participants was 70 years and was similar among 
patients included in the 3 studies. The meta-analysis of 6 trials that compared adjusted-dose warfarin 
with placebo/no treatment included a similar proportion of patients with previous stroke/TIA as the 
ARISTOTLE trial (20% and 19%, respectively). The meta-analysis of 8 trials that compared 
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antiplatelet therapy with placebo/no treatment included twice as many participants with previous 
stroke/TIA as the AVERROES trial (29% and 14%, respectively).  
 
Apixaban, warfarin, and placebo 
The number of deaths and death rates in the trials are compared in Table 2. In the Hart meta-analysis, 
a lower rate of death was seen with warfarin compared with placebo/no treatment (7.6% vs. 9.9%, OR 
0.74, 95% CI 0.57–0.97) [1]. In ARISTOTLE, apixaban reduced the risk of death compared with 
warfarin (6.6% vs. 7.4%, OR 0.89, 95% CI 0.79–0.99) [4]. When compared with an imputed placebo, 
apixaban reduced the risk of death by 34% (95% CI 12–50%; p=0.004).  
 
Apixaban, aspirin, and placebo 
In the Hart meta-analysis, a numerically lower rate of death was seen with aspirin compared with 
placebo/no treatment (9.6% vs. 11.2%, OR 0.86, 95% CI 0.69–1.07) [1]. In AVERROES, apixaban 
tended to reduce the risk of death compared with aspirin (4.0% vs. 5.0%, OR 0.78, 95% CI 0.60–1.01) 
[9]. When compared with an imputed placebo, apixaban reduced the risk of death by 33% (95% CI 6–
52%; p=0.02).  
 
Apixaban versus placebo 
Figure 2 summarizes the complete imputed placebo analysis. The overall estimate for a lower risk of 
death with apixaban compared with placebo is 34% (95% CI 18–47%; p=0.0002).  
 
DISCUSSION 
In a standard meta-analysis approach using data from previously published meta-analyses comparing 
warfarin with placebo and aspirin with placebo in the ARISTOTLE and AVERROES trials, we have 
demonstrated that apixaban reduces all-cause death by approximately one-third compared with 
placebo. While this method does not replace direct placebo-controlled studies, it implies that one may 
expect a large relative risk reduction in mortality when apixaban is used, rather than no therapy, in 
this patient population. This finding is particularly important because patients with AF have a 
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markedly elevated risk of death as well as stroke. Compared with warfarin, all NOACs resulted in 
numerically lower rates of death, and it is likely that all of them have a similar treatment effect on 
mortality when compared with placebo. The unique aspect of the apixaban program is that there were 
2 large randomized trials (apixaban vs. warfarin; apixaban vs. aspirin). This allows an assessment of 
the effect of apixaban on mortality in patients with AF through a network meta-analysis of apixaban, 
warfarin, aspirin, and no antithrombotic therapy control.  
Regulatory authorities usually require 2 positive placebo-controlled trials as evidence for 
approval of new treatments. However, once a therapy is definitely proven to be effective for a target 
disease, there may no longer be equipoise to randomize patients to placebo; thus, placebo-controlled 
trials may no longer be feasible or even ethical [13]. New therapies targeting the same therapeutic 
pathway must therefore be compared with the existing “gold standard.” Of course this means that the 
direct effect of the new therapy compared with placebo is unknown. However, this can be addressed 
indirectly using historical data from the trials that compared the original gold standard with placebo 
[14]. This type of analysis may not provide enough evidence to justify a regulatory claim for the new 
agent, but it can help define the magnitude of the experimental drug effect on the outcome of interest. 
Ideally, in order to use this statistical approach, certain assumptions should be met. The populations 
and outcomes studied should be similar and the active control and reference trials should have used 
the same drug and in the same way. Overall, the meta-analysis and trials included in our analysis 
enrolled patients with AF and similar demographic profiles. The mean CHADS2 score was similar 
among the ARISTOTLE and AVERROES studies. This risk score was not available at the time of 
trials comparing antithrombotic therapies with placebo. A considerable proportion of the participants 
in Hart et al. had previous history of stroke/TIA; thus, we may reasonably infer that these patients 
were also at high risk of stroke. 
In ARISTOTLE and AVERROES, apixaban was used at a dose of 5 mg twice daily and the 
criteria for receiving a lower dose of apixaban were similar among these trials. In ARISTOTLE, dose-
adjusted warfarin was given with a target INR of 2.0 to 3.0, and the median time in therapeutic range 
was 66% in warfarin-treated subjects. In Hart et al., the mean achieved INR ranged from 2.0 to 2.6 
among warfarin-treated participants in 5 trials of primary prevention and was 2.9 in a single 
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secondary prevention trial. Regarding the aspirin dose, some differences among the studies should be 
highlighted. In AVERROES, the majority of participants (90.6%) received aspirin at a dose that 
ranged between 81 to 161 mg. In Hart et al., approximately half of the participants in trials that 
compared aspirin with placebo/no treatment received aspirin in a dose equal to or lower than 150 mg, 
whereas the other half received an aspirin dose of 300–325 mg. However, it has been previously 
shown that aspirin doses of 75–150 mg daily are at least as effective as higher doses for the 
prevention of ischemic events [15]. Thus, it is unlikely that the dose of aspirin played any role in our 
findings. Finally, since the effects of apixaban on reducing stroke versus warfarin and versus aspirin 
are clear, we elected to instead focus exclusively on its impact on mortality. 
 Patients with AF are at increased risk of stroke and systemic embolism. However, 
thromboembolic events do not lead to the majority of deaths observed in these patients. Several 
analyses have shown that most participants in clinical trials of AF died from other cardiovascular 
causes such as sudden cardiac death and heart failure [16-18]. Additionally, ICH is a devastating 
complication of anticoagulation therapy in this population, resulting in a fatality rate of 40–50% in the 
30 days after ICH [19-21]. Moreover, in a study of older adults, premature death was the most 
common event within 5 years of a new diagnosis of AF; and, as expected, the risk of death was 
greater than the risk of stroke in this population [22]. Strategies to improve survival in patients with 
AF are needed. Management of cardiovascular risk factors and appropriate treatment of comorbidities 
may help improve survival in patients with AF. Oral anticoagulation is the mainstay for stroke 
prevention in patients with AF. We have observed that apixaban, as compared with warfarin, was 
effective in reducing mortality in patients with AF [4], and this effect versus no antithrombotic 
therapy was even greater when using indirect comparisons with a putative placebo. A possible 
explanation for the benefit of apixaban over warfarin on mortality is the reduction in bleeding events, 
particularly ICH [23]. We have shown that apixaban caused significantly less ICH than warfarin, 
regardless of type (spontaneous or traumatic) and location (intraparenchymal, subdural, or 
subarachnoid) [24]. It is also likely that by reducing stroke (and potentially myocardial infarction), 
apixaban might further reduce cardiovascular deaths. Thus, the impact of apixaban on mortality may 
be primarily due to cardiovascular causes, similar to what has been shown with other NOACs [16,18].  
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Our results must be interpreted in light of several limitations. We performed indirect 
comparisons and meta-analysis, and the statistical methods used do not replace the value of placebo-
controlled trials. However, a placebo-controlled study in this clinical setting would not be feasible. 
Although the participants of the studies were demographically similar, we were unable to assess the 
CHADS2 score in patients included in Hart et al.  
 
CONCLUSION 
A meta-analysis suggests that apixaban reduces all-cause death by 34% (18–47%) in comparison with 
an imputed placebo. Thus, in addition to preventing stroke among patients with AF and risk factors 
for stroke, there is evidence that apixaban substantially reduces mortality in these patients.  
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Figure Legends 
Figure 1. Title: Analysis design. Caption: Schematic of the trials and comparisons used in the 
putative placebo analysis. 
Figure 2. Title: Odds ratio plot. Caption: Treatment effect of apixaban in all-cause death in putative 
placebo analysis.   
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Table 1. Selected characteristics of trials and participants 
 Hart et al.1 ARISTOTLE AVERROES 
Treatments Adjusted-dose warfarin 
vs. placebo/ no 
treatment 
Antiplatelet therapy 
vs. placebo/ no 
treatment 
Apixaban vs. 
warfarin 
Apixaban vs. 
aspirin 
Year of publication 2007 2007 2011 2011 
Number of trials 6 8 - - 
Number of participants 2900 4876 18201 5599 
Follow-up (years) 1.6 1.7 1.8 1.1 
Participants     
Age (yrs) 69 69 70 70 
Female (%) 29 37 35 41 
Previous stroke/TIA (%) 20 29 19 14 
Hypertension (%) - - 87.5 86.4 
Diabetes (%) - - 25.0 20.0 
CHADS2 - - 2.1 2.1 
TIA=transient ischemic attack. 
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Table 2. Number of deaths and death rates in trials 
Apixaban vs. Placebo using Warfarin as Active Control 
 Apixaban* Warfarin* Placebo* Comparison OR (95% CI) p-value 
ARISTOTLE 603/9120 (6.6) 669/9081 (7.4) -- Apixaban vs.  
Warfarin 
0.890 (0.794–0.998)  
Hart et al.(1) -- 110/1450 (7.6) 143/1450 (9.9) Warfarin vs.  
Placebo 
0.740 (0.570–0.970)  
Indirect 
estimate 
   Apixaban vs.  
Placebo 
0.659 (0.495–0.876) 0.004 
Apixaban vs. Placebo using Aspirin as Active Control 
 Apixaban Aspirin Placebo Comparison OR (95% CI) p-value 
AVERROES 111/2807 (4.0) 140/2791 (5.0) -- Apixaban vs. 
Aspirin 
0.780 (0.604–1.006)  
Hart et al.(1) -- 184/1912 (9.6) 204/1818 (11.2) Aspirin vs. 
Placebo 
0.860 (0.690–1.070)  
Indirect 
estimate 
   Apixaban vs. 
Placebo 
0.670 (0.479–0.939) 0.020 
Apixaban vs. Placebo Combined 
Indirect 
estimate 
   Apixaban vs. 
Placebo† 
0.664 (0.534–0.825) 0.0002 
*Cells contain number of deaths / number of patients (% of patients) 
†Heterogeneity p-value: 0.959. 
CI=confidence interval; OR=odds ratio. 
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Figure 1.
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Figure 2.
 
